Business Wire

AMP-ROBOTICS

30.5.2022 08:02:04 CEST | Business Wire | Press release

Share
​​AMP Robotics Continues European Expansion

AMP Robotics Corp. (“AMP”), a pioneer in AI, robotics, and infrastructure for the waste and recycling industry, continues to expand its presence in Europe to meet the demand for its AI and automation solutions and provide dedicated local support and service for the market. The company is exhibiting at IFAT 2022 , May 30-June 3 in Munich, for the first time.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220529005046/en/

AMP installed its first AI-guided robotics systems in the UK and Ireland with Recyco in September 2021 and has since deployed more recycling solutions throughout Europe, including at FCC Medio Ambiente/Environment in Spain. AMP has grown its team to include sales support, training, service, and marketing, in addition to direct sales staff focused on serving Austria, Belgium, France, Germany, Luxembourg, The Netherlands, and Switzerland, along with the UK and Ireland.

“AMP is the leading brand in robotics, and that was an important factor for us in choosing a solution to improve our sorting productivity and efficiency,” said Alfredo Vigre, project manager, Waste Treatment Department, FCC Medio Ambiente/Environment. “We tested the robot prior to implementation and were pleased with its ability to recognize and recover materials that optical sorters cannot. It’s been fast and effective, and a great tool for quality control.”

AMP provides a portfolio of recycling solutions powered by its industry-leading neural network, which is built on a data engine that has recognized more than 50 billion containers and packaging types ​​​​​in real-world conditions. AMP Cortex™ is the company’s high-speed robotic sorting system with approximately 230 deployments in more than 80 facilities across three continents. AMP’s install base is the largest known fleet of recycling robots in the world, creating the most expansive neural network of field data for recycled materials. AMP Vision™ is a modular computer vision system that helps operators understand material flow throughout key stages of sorting operations and serves as a quick and efficient alternative to manual sampling audits. When integrated with AMP Clarity™, the company’s material characterization and robot performance software solution, users can monitor real-time material characterization and performance measurement throughout a facility. AMP recently introduced new Clarity features including mass estimation; robot pick assignments, alerts, and status tracking; and expanded reporting capabilities.

“We’re seeing strong interest in and satisfaction with our AI and robotics technology here in Europe thanks to our technological leadership,” said Gary Ashburner, general manager, Europe, for AMP Robotics. “Our AI platform, AMP Neuron, continues to achieve breakthroughs in data accuracy and classification of different polymers, form factors, and other packaging types, which is helping our customers take a more data-driven approach to increasing recovery, lowering costs, and optimizing operations.”

At IFAT, AMP’s European-based team will provide live demonstrations of the company’s vision system for material characterization at booth 546 in Hall B6.

“As we continue to scale our business and innovate new ways to improve the economics of recycling, we’re committed to the European market and our growing customer base there,” said Matanya Horowitz, founder and CEO of AMP Robotics. “Our efforts to modernize Europe’s recycling infrastructure are important to our global investors, and critical to realizing our vision of a world without waste.”

About AMP Robotics® Corp.

AMP Robotics is modernizing the world’s recycling infrastructure by applying AI and automation to increase recycling rates and economically recover recyclables reclaimed as raw materials for the global supply chain. The AMP Cortex™ high-speed robotics system automates the identification and sorting of recyclables from mixed material streams. The AMP Neuron™ AI platform continuously trains itself by recognizing different colors, textures, shapes, sizes, patterns, and even brand labels to identify materials and their recyclability. Neuron then guides robots to pick and place the material to be recycled. Designed to run 24/7, all of this happens at superhuman speed with extremely high accuracy. AMP Clarity™ provides data and material characterization on what recyclables are captured and missed, helping recycling businesses and producers maximize recovery. With deployments across North America, Asia, and Europe, AMP’s technology recovers recyclables from municipal collection, precious commodities from electronic scrap, high-value materials from construction and demolition debris, and valuable feedstocks from organic material.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye